Bachem Holding (BCHMY) Fair Value & Analysis
Healthcare · US · Market cap $6.7B
Bachem Holding
BCHMY · US
Fair value as of: Jun 24, 2026
From 16 valuation models · updated 7 days ago
Fair value updated Jun 24, 2026 — revised from $4.23 to $4.22 (−0.2%) since Jun 23, 2026. Share price +5.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $5.04 – $9.38 · fair‑value band $2.95 – $5.49 · the $8.40 price screens above the $4.22 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bachem Holding (BCHMY) currently trades at $8.40, while our model-based Fair Value estimate is $4.22 — implying the stock looks roughly 49.8% overvalued today. We read business quality at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Bachem Holding generated revenue of $695M at a net margin of 21.4%. Revenue grew 4.7% year over year. It earns a return on equity of 10.4%. The stock trades on a trailing P/E of 36.0. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bachem Holding reported revenue of $695M in FY2025 versus $503M in FY2021, a compound +8.4%/yr. Reported net income was $149M in FY2025, compounding +6.7%/yr from FY2021.
Is BCHMY fairly valued? → Check now
Recent news
- Bachem Holding (SWX:BANB) Stock Valuation Check After Recent Share Price Pullback
- Bachem Holding AG Announces Capital Markets Day 2026
- Bachem Announces Changes to the Corporate Executive Committee
- Bachem Annual General Meeting 2026
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bachem Holding (BCHMY) undervalued?
What is the fair value of BCHMY?
What is the quality score of BCHMY?
What is the revenue of Bachem Holding (BCHMY)?
What is the net profit margin of BCHMY?
Does Bachem Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.